Literature DB >> 24726669

[Acute cough in infants: impact on families and pharmacists of contraindications of the Agence nationale de sécurité du médicament et des produits de santé (ANSM)].

F Alauzet1, S Blanc2, I Montaudié3, C Piccini-Bailly3, M Berlioz-Baudoin2, M Bégassat2, M Albertini2, L Giovannini-Chami2.   

Abstract

CONTEXT AND
OBJECTIVE: Although commonplace and usually not serious, acute cough in the context of upper respiratory tract infection is a frequent reason for consultation and generates significant parental anxiety. Parents often request active drug intervention. Following the contraindications in infants of mucolytics, Hélicidine(®), antihistamines, and terpene-based suppositories, issued between 2010 and 2011 by the Agence nationale de sécurité du médicament et des produits de santé (ANSM), we wished to assess whether these contraindications were known by parents and applied in pharmacies.
MATERIALS AND METHODS: An assessment of compliance with these contraindications was made by a double declarative prospective observational study in Nice, first with 29 pharmacists and pharmacy technicians (4-25 August 2012) and then with 289 parents of infants (December 2011 to April 2012).
RESULTS: The rate of noncompliance with contraindications was 23.8 % for parents and 34.5 % of pharmacists and pharmacy technicians. Consumption of cough medicines was inversely correlated to the ability to perform a correct nasal wash (OR=2.3). Only 21 % of parents used nasal wash properly. Full-time work was a risk factor for noncompliance with contraindications (OR=1.91).
CONCLUSION: ANSM contraindications still have a limited impact on pharmacists and families. Therefore, efforts must be pursued to stop delivering cough medicines for infants. The information and educational campaigns should also involve parents and help to improve nasal wash use.
Copyright © 2014 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24726669     DOI: 10.1016/j.arcped.2014.02.026

Source DB:  PubMed          Journal:  Arch Pediatr        ISSN: 0929-693X            Impact factor:   1.180


  2 in total

1.  Statistical issues in first-in-human studies on BIA 10-2474: Neglected comparison of protocol against practice.

Authors:  Sheila M Bird; Rosemary A Bailey; Andrew P Grieve; Stephen Senn
Journal:  Pharm Stat       Date:  2017-02-16       Impact factor: 1.894

2.  Commitments by the biopharmaceutical industry to clinical trial transparency: the evolving environment.

Authors:  Slavka Baronikova; Jim Purvis; Eric Southam; Julie Beeso; Antonia Panayi; Christopher Winchester
Journal:  BMJ Evid Based Med       Date:  2019-03-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.